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Abstract There are currently no effective pharmacological
agents available to stop or prevent the progression of
Huntington’s disease (HD), a rare hereditary neurodegen-
erative disorder. In addition to psychiatric symptoms and
cognitive impairments, HD causes progressive motor dis-
turbances, in particular choreiform movements, which are
characterized by unwanted contractions of the facial mus-
cles, trunk and extremities. Management of choreiform
movements is usually advised if chorea interferes with
daily functioning, causes social isolation, gait instability,
falls, or physical injury. Although drugs to reduce chorea
are available, only few randomized controlled studies have
assessed the efficacy of these drugs, resulting in a high
variety of prescribed drugs in clinical practice. The current
pharmacological treatment options to reduce chorea in HD
are outlined in this review, including the latest results on
deutetrabenazine, a newly developed pharmacological
agent similar to tetrabenazine, but with suggested less peak
dose side effects. A review of the existing literature was
conducted using the PubMed, Cochrane and Medline
databases. In conclusion, mainly tetrabenazine, tiapride (in
European countries), olanzapine, and risperidone are the
preferred first choice drugs to reduce chorea among HD
experts. In the existing literature, these drugs also show a
beneficial effect on motor symptom severity and
improvement of psychiatric symptoms. Generally, it is
recommended to start with a low dose and increase the
dose with close monitoring of any adverse effects. New
interesting agents, such as deutetrabenazine and
pridopidine, are currently under development and more
randomized controlled trials are warranted to assess the
efficacy on chorea severity in HD.
Key Points
Tetrabenazine is the only drug approved by the US
FDA for the treatment of chorea in Huntington’s
disease (HD). Monitoring for adverse effects such as
depressive symptoms and suicidal behavior is
warranted, especially in patients with a history of
depression.
In addition to a beneficial effect on chorea,
olanzapine, risperidone, and tiapride also seem to
have a positive effect on sleep dysfunction, mood
disturbances, and the prevention of weight loss.
Potential dopamine-stabilizing and -depleting drugs
to reduce motor symptoms in HD are currently under
investigation in large multicenter clinical trials.
1 Introduction
Huntington’s disease (HD) is an inherited autosomal
dominant progressive neurodegenerative disorder, with an
estimated prevalence of 5–10 per 100,000 in the Caucasian
population [1, 2].
The disease is clinically characterized by motor distur-
bances, cognitive decline, and psychiatric symptoms. One
of the most recognized motor signs in HD is chorea, which
is characterized by unwanted muscle contractions that are
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progressive over time and interfere in activities of daily
living [3].
HD is caused by a cytosine-adenine-guanine (CAG)
trinucleotide repeat expansion in the huntingtin protein
located on chromosome 4p16.3 [4]. The mutant huntingtin
accumulates within brain cells, causing cell toxicity and
dysfunction of neurons throughout the brain when the
disease progresses. Neuropathological alterations are found
widely throughout the brain, but the primary focus of
atrophy is located in the striatum and cerebral cortex [5, 6].
The distinct striatal atrophy is caused by extensive loss of
striatal medium-sized spiny neurons that is suggested to
result in the choreiform movements seen in HD [7, 8].
Effective pharmacological treatment to stop the patho-
physiological process underlying HD is unfortunately not
available. Pharmacological treatment is therefore focused
on improving daily functioning by reducing symptom
severity [9, 10].
Although many potential effective pharmacological
options for the treatment of chorea are available, only few
randomized controlled studies have been performed that
assess the effects on symptom reduction. To date, practice-
based studies showed that among HD experts, there is a
wide variety in preferred drugs to treat chorea [10, 11].
Non-pharmacological treatment approaches to reduce
chorea are currently also under investigation. For example,
pallidal deep brain stimulation (DBS) has been shown to be
a safe treatment option [12]. The effects of DBS on motor
symptoms are currently under examination in a larger
follow-up study.
A review of the existing literature about the pharma-
cological treatment of chorea in HD was conducted using
the PubMed, Cochrane and Medline databases. All litera-
ture published before September 2016 was critically
reviewed. This review describes the different treatment
options that are currently available to reduce chorea in
patients with HD.
Also, we will give an outline of current clinical trials
involving the latest experimental pharmacological
approaches. An overview of the reviewed literature and
their most relevant findings is provided in Table 1.
2 Huntington’s Disease (HD)
2.1 Clinical Features
Huntington’s disease is characterized by increasingly sev-
ere motor disturbances, cognitive impairment, and psy-
chiatric symptoms [1, 13]. The mean age of disease onset is
between 30 and 50 years (ranging from 2 to 85 years), with
the mean duration of the disease between 17 to 20 years
[1]. The disease can also occur in early childhood (juvenile
HD) or later in life [14]. The clinical onset of HD is still
determined by the manifestation of typical motor distur-
bances, although psychiatric or cognitive dysfunction can
be present many years before the onset of motor signs [15].
Cognitive impairment may involve problems with working
memory, executive dysfunction, and attention deficits,
which progress gradually [16]. Behavioral and psychiatric
symptoms in HD include apathy, depression, irritability
and aggression, and obsessive-compulsive behavior [13].
The presence and severity of motor disturbances can
vary individually but can be divided into involuntary
movements such as chorea, dystonia, and tics, and
impairments in voluntary movements such as hypokinesia,
apraxia, and motor impersistence. Chorea is defined as
unwanted, rapid, irregular movements of the extremities
and facial jerking, and is usually present in the early stage
of the disease [17]. The severity of choreiform movements
can vary from very subtle twitches involving the eyebrows
or upper face to severe, generalized contractions involving
the trunk and limbs that can flow from one extremity to
another randomly [3]. Chorea may also interfere with
speech, swallowing, gait, and balance [3]. Furthermore, the
intensity of the choreiform movements can be influenced
by emotions and other stress factors, such as fatigue and
anxiety [3].
Dystonia is more often seen in more progressed disease
stages and is characterized by sustained or intermittent
muscle contractions leading to abnormal posture of the
trunk and extremities [1, 18].
The degree of motor impairment is commonly assessed
with the Unified Huntington’s Disease Rating Scale–Total
Motor Scale (UHDRS–TMS), a clinical tool that quantifies
the severity of motor impairment, with scores ranging from
0 to 124, with higher scores indicating more severe motor
impairment [19]. Here, chorea severity is scored for seven
different body areas on a scale from 0 to 4 (with a maxi-
mum total chorea score of 28).
2.2 Chorea and Quality of Life
Patients with HD are not always aware of the severity of
the choreiform movements. However, the progressive
nature of motor symptoms in HD impacts daily functioning
and interferes with social activities [20]. In later disease
stages, the severity of chorea is an independent predictor of
fall frequency and gait disturbance [21] and is often the
reason for nursing-home placement [22]. Studies investi-
gating the health-related quality of life showed that gait
impairments, bradykinesia, and choreiform movements are
major contributors to an impaired quality of life for both
patients with HD and their caregivers [23, 24].
Specialists start symptomatic treatment in HD in con-
sultation with the patient and family when chorea is
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causing balance disturbances, falls, and physical injury,
and when it interferes with daily functioning at work and at
home [3, 10]. In a Europe-wide assessment of medication
use among HD patients, 39.3% of all registered HD
patients received medication for the treatment of chorea,
comprising dopamine depleting drugs, antipsychotics, or
antiparkinsonian medication [25].
2.3 Neurotransmission in HD
In the normal human brain, the striatum comprises up to
95% of medium spiny neurons. These projection neurons
are involved in the feedback loop that suppresses invol-
untary movements. In HD, atrophy of the striatum is the
pathological hallmark of the disease and the medium spiny
neurons are the most affected cells [7, 26]. Loss of medium
spiny neurons causes abnormal neurotransmission of the
dopamine, glutamate, and gamma-amino butyric acid
(GABA) systems and is therefore the main focus of phar-
macotherapy in HD [9].
Dopamine is a major neurotransmitter that is involved in
movement control, cognition, motivation, reward process-
ing, and emotion modulation [27, 28]. Specific dopamine
receptors are widely expressed throughout the central
nervous system and are activated by dopamine on pre- and
post-synaptic neurons. Free, unbound dopamine can be
transported to the pre-synaptic terminal via the high-
affinity dopamine transporter (DAT). Here, it is re-pack-
aged into vesicles by the vesicular monoamine transporter
type 2 (VMAT2) or broken down into inactive metabolites
by enzymes such as monoamine oxidase [28].
The neurodegenerative processes in HD cause mainly
postsynaptic dopaminergic dysfunction of dopaminergic
type 1 (D1) and type 2 (D2) receptors in the striatum
[28–30].
Dopaminergic dysfunction is found in both premanifest
and manifest HD, where manifest patients show a greater
loss of striatal D1 and D2 receptor binding [31, 32].
In PET studies, this decrease in dopamine receptor
binding seems to be correlated with clinical motor assess-
ment (UHDRS-TMS), functional capacity scores, and
assessments that measure executive dysfunction [33].
As it is hypothesized that choreiform movements in HD
are related to overstimulation of dopamine receptors,
pharmacological agents that modify the activity of the
dopaminergic system have been of specific interest. Still,
the glutamate neurotransmitter system is already affected
in early disease stages and it is suggested that increased
glutamatergic neurotransmission in the thalamocortical
pathways also contributes to hyperkinetic movements [7].
Further, it is proposed that modulation of peripheral
manifestations of the disease, such as signs of the muscu-
lar, circulatory, metabolic, and digestive systems, might
offer new approaches to therapeutic development and can
have an additional positive effect on motor symptoms [34].
In the following paragraphs, we discuss the available
drugs for treating chorea in patients with HD classified by
neurotransmitter affinity.
3 Pharmacological Treatment of Chorea in HD
3.1 Tetrabenazine
Tetrabenazine was synthesized in 1956 and first introduced
in the 1970s for the management of hyperkinetic move-
ment disorders [35]. Tetrabenazine is a reversible dopa-
mine-depleting drug that selectively binds to the central
VMAT2 and depletes monoamines by inhibiting their
transport into presynaptic vesicles [36, 37].
Tetrabenazine is rapidly metabolized into two metabo-
lites, alpha- and beta-dihydrotetrabenazine via CYP2D6, a
hepatic isoenzyme, with maximum concentrations reached
in 1.5 h after dosing [38]. Elimination of tetrabenazine and
its metabolites is primarily renal. As the half-life of the
metabolites is between 2 and 8 h [38, 39], tetrabenazine
should be administered two to three times daily.
The TETRA-HD study, the first randomized controlled
dose-finding study of tetrabenazine conducted by the
Huntington Study Group (HSG), demonstrated the efficacy
of tetrabenazine in HD [39]. This study was essential for
the US Federal Drug Administration (FDA) approval of
tetrabenazine as a treatment for chorea. Since 2008, tetra-
benazine is the only drug that the FDA has approved for the
treatment of chorea in HD and is also available in Canada,
Australia, New Zealand, and Western Europe.
In the TETRA-HD study, participants with HD received
tetrabenazine (n = 54) or placebo (n = 30) for 12 weeks
[39]. Tetrabenazine was titrated weekly in 12.5 mg incre-
ments up to a maximum dosage of 100 mg per day. After
12 weeks of treatment, there was a significant reduction of
chorea severity by 5.0 units on the UHDRS total chorea
score (SD 0.5, p\ 0.0001) in the tetrabenazine group
compared with a reduction of 1.5 units (SD 0.7) in the
placebo group. Overall, this represents an average reduc-
tion in chorea severity of 23.5% due to tetrabenazine.
There was, however, no improvement on the total motor
score of the UHDRS.
To assess the long-term safety and efficacy of tetra-
benazine in the treatment of chorea in HD, participants
who completed the TETRA-HD study were invited to
participate in the open-label extension study for up to
80 weeks [40]. In this study, participants were titrated to
the best individual dose with a maximum of 200 mg per
day, with a mean dosage at week 80 of 63.4 mg (range
12.5–175 mg). In total, 45 of the 75 initially enrolled
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participants completed the 80-week trial. After 80 weeks of
treatment, there was a significant reduction of mean
UHDRS total chorea score of 4.6 units (SD 5.5, p\ 0.001).
After a washout period of 1 week, participants on tetra-
benazine showed an increase in chorea severity, demon-
strating a symptomatic advantage of tetrabenazine [39, 40].
The effectiveness of tetrabenazine for the treatment of
chorea was additionally confirmed by several other small
observational and open-label studies [41–44].
However, besides the overall symptomatic advantage of
tetrabenazine in reducing chorea in these clinical trials,
many adverse effects have been reported, thus limiting its
clinical benefit. The most commonly reported adverse
effects include sedation, fatigue, depression, anxiety, aka-
thisia, agitation, dysphagia, nausea, parkinsonism, and
dystonia [39–44] (Table 2).
Some adverse effects seem to be related to peak con-
centrations of active circulating metabolites and can be
managed by dose reduction. Nevertheless, depression and
suicidal behavior can be exacerbated by tetrabenazine,
especially in patients with a history of depressive mood.
Tetrabenazine is therefore contraindicated in patients who
are actively suicidal and in patients with inadequately
treated depression [35]. Furthermore, concomitant treat-
ment with antidepressant drugs that have strong CYP2D6-
inhibiting effects (such as fluoxetine and paroxetine) can
lead to increased levels of the active metabolite due to a
prolonged half-life. In case of concomitant use of CYP2D6
inhibitors, a 50% reduction of the daily tetrabenazine dose
is recommended [10].
A Cochrane review examined 22 studies with various
pharmacological interventions for the symptomatic treat-
ment of HD that were published up to December 2007 [2].
The authors of the Cochrane review conclude that only
tetrabenazine showed a clear effect in reducing chorea in
HD based on the results of the TETRA-HD study.
In clinical practice, many specialists prefer tetra-
benazine as a first choice therapy if there are no signs of
depressive symptoms or suicidal behavior [25, 45].
Combining these results, tetrabenazine seems generally
safe and well tolerated, with dose-dependent adverse
effects. It is recommended to prescribe tetrabenazine in the
absence of severe depression and psychosis [46]. Tetra-
benazine must be started at a low dosage (12.5–25 mg per
day) and titrated with small increments to a therapeutic
dosage of 50–75 mg per day (the maximum dosage is
100–200 mg/day), with monitoring after each titration.
Frequent dosing is required due to the short half-life of the
active metabolites. It is therefore suggested that the total
daily dosage of tetrabenazine should be divided over two to
four doses per day. It can also be helpful to administer the
main dosage at night, because of the potentially sedative
adverse effects. In addition, patients must be closely
monitored for the development of depressive symptoms or
suicidal ideation.
3.2 Dopamine Antagonists
It is suggested that the effect of dopamine antagonists in
the treatment of chorea is caused by blocking postsynaptic
dopamine D2 receptors leading to the suppression of chorea
[47]. Another hypothesis is that the observed symptomatic
effect is due to nonspecific or sedating effects [48].
Besides the potential positive effects on choreatic
symptoms, dopamine antagonists are known to cause
adverse effects due to dopamine D2 receptor blockage.
Adverse effects include dyskinesias, rigidity, cognitive
impairment, hypotension, and sedative effects.
In 2012, the American Academy of Neurology (AAN)
presented an evidence-based guideline for the pharmaco-
logical treatment of chorea [49]. The authors conclude that
there was insufficient data available to make recommen-
dations regarding the use of dopamine antagonists, as
evidence of the efficacy of dopamine antagonists on chorea
is based on small clinical trials and case reports. However,
according to an international group of HD experts,
antipsychotic drugs were a first-choice treatment option in
most North American and European countries, especially
when psychiatric symptoms such as psychosis, depression,
or aggressive behavior were present [10].
Typical first-generation antipsychotic drugs are cur-
rently less popular in clinical practice because of the risk of
extrapyramidal adverse effects, such as tardive dyskinesia
and because of their sedative effects. Modern second-
generation atypical antipsychotic drugs (such as risperi-
done, olanzapine, and quetiapine) are mainly preferred by
clinicians, as these drugs generally provide better tolera-
bility than first-generation antipsychotics [10]. Here, we
discuss the most commonly prescribed and studied dopa-
mine antagonists for the treatment of chorea in HD.
Table 2 presents a summary of the most frequently pre-
scribed drugs to treat chorea in HD including commonly
reported adverse effects, contraindications, and drug
interactions.
3.2.1 Tiapride
Tiapride is a first-generation D2 receptor antagonist that is
only available in European countries. Although tiapride is a
classic antipsychotic drug, it is a frequent choice for the
treatment of chorea by HD experts [10, 11]. In a survey
among international HD experts, 50% of the European
respondents regarded tiapride as the first choice for treating
treat chorea [10].
Tiapride has an oral bioavailability of about 75%, with
peak plasma concentrations reached in 1 h after oral
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administration, a half-life of 2.6–4 h, and is eliminated
mostly by urinary excretion [50].
Only two small randomized, controlled studies have
been performed to assess the efficacy of tiapride on
choreatic symptoms [51, 52]. Little interest from the
pharmaceutical industry to evaluate the efficacy of tiapride
on chorea might be an explanation for the lack of adequate
studies having been performed.
A double-blind, controlled, crossover study investi-
gated the effect of tiapride in 22 HD patients [51].
Choreatic symptoms were assessed using video record-
ings at several time points. Although individuals subjec-
tively responded well to the tiapride treatment, the authors
did not find a significant reduction of choreiform move-
ments after treatment with 300 mg tiapride per day for
2 weeks.
Another randomized double-blind study with 29 HD
patients examined the effect of tiapride with placebo using
a crossover design of two 3-week periods of tiapride
alternated with a single 3-week placebo period [52]. Six
patients did not finish the different treatment periods, two
of whom because of drug-related adverse effects. Patients
were administered 1200 mg tiapride in the morning,
900 mg in the afternoon, and another 900 mg in the eve-
ning. Choreiform movement of the face, neck, trunk, and
extremities were assessed on a 4-point severity scale. After
treatment with tiapride, patients showed a significant
reduction of choreiform movements in four out of five
body regions (head, p = 0.00; trunk, p = 0.05; upper
limbs, p = 0.01; lower limbs, p = 0.01). However, these
results should be interpreted with caution, as no wash-out
period between tiapride and placebo periods was per-
formed, which is preferred with crossover study designs.
Reported adverse effects include sedative effects such as
drowsiness and extrapyramidal signs [51, 52].
Although the existing evidence does not show a favor-
able effect of tiapride on chorea, tiapride is widely used by
European clinicians in daily practice [25].
3.2.2 Clozapine
Clozapine is an atypical neuroleptic drug commonly used
in the treatment of schizophrenia [53]. Since clozapine has
a low incidence of extrapyramidal side effects, it is also
suggested to be a suitable symptomatic drug for chorea.
Clozapine has a relatively high affinity for dopamine D1
and D4 receptors and relatively low D2 dopaminergic
antagonistic properties in contrast to typical neuroleptic
drugs [53]. Orally, clozapine is rapidly absorbed and
reaches peak plasma concentration in approximately 3 h
[53]. Clozapine is eliminated by hepatic cytochrome
isoenzymes with an elimination half-life of 14 h. Sertra-
line, paroxetine, and fluoxetine have been reported to
increase plasma concentrations of clozapine, whereas co-
administration with carbamazepine or rifampin reduced
clozapine plasma concentrations [53].
Two small studies (n = 3 and n = 5, respectively)
reported clear reductions in abnormal involuntary move-
ments in patients with HD at different dosages between 50
and 500 mg per day [54, 55]. However, a randomized
double-blind trial conducted in 33 patients with HD
reported only a small beneficial effect of clozapine in the
reduction of chorea [56]. In this study, patients received
clozapine up to a maximum dosage of 150 mg clozapine
(n = 17) or placebo (n = 16) per day for a period of
31 days. A small reduction of chorea (0.7 units) on the
UHDRS total chorea score was seen, but this was not
significant (p = 0.81). Conversely, there were significant
adverse events reported, including fatigue, dizziness,
walking difficulties, and hypersalivation. Overall, eight
patients needed a reduction of clozapine dosage and
another six patients were unable to complete the trial
because of adverse reactions. Therefore, the authors do not
advise the use of clozapine for the treatment of chorea. In
clinical practice studies, clozapine is not prescribed to treat
chorea in HD [10, 25].
3.2.3 Olanzapine
In the UK, olanzapine is the most commonly prescribed
dopamine antagonist for the treatment of motor and
behavioral symptoms in HD [11]. Olanzapine is an atypical
antipsychotic drug with a broad pharmacokinetic profile
with high affinity for serotonergic (5HT2A, 5HT2C, 5HT3)
receptors, but antagonizes dopamine (D2) receptors
[57, 58]. Olanzapine has a oral bioavailability of 60%, as
40% is inactivated by first-pass hepatic metabolism [58].
Olanzapine reaches a maximum plasma concentration
within 5–8 h and has a mean half-life in healthy individuals
of approximately 33 h. Fluvoxamine or estrogens
(CYP1A2 inhibitors) have been shown to increase plasma
concentrations of olanzapine, whereas carbamazepine,
omeprazole, and rifampin (CYP3A4 inducers) may reduce
olanzapine plasma concentrations [58, 59].
Several case reports and small open-label studies have
been performed to assess the anti-choreiform effect of
olanzapine in HD patients [60–63]. In a 6-month open-
label trial of olanzapine, 11 patients with HD received
5 mg olanzapine per day and reported a significant effect
on behavioral subscores (depression, anxiety, irritability,
and obsessive symptoms) [61]. Although a moderate
improvement in chorea score (mean reduction of 1.6 units)
was also observed, this effect was not significant.
Following up on this study, a prospective open-label study
administered olanzapine in increasing doses (max
30 mg/day, mean dosage of 15.6 mg/day) to nine
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predominantly choreatic HD patients [62]. No adverse events
were reported. After 2 weeks of treatment with olanzapine,
UHDRS chorea scores improved from 13.4 (SD 6.8) before
treatment to 6.9 (SD 5.0) after treatment with olanzapine.
The authors state that six patients continued treatment with
olanzapine after the study for a period of 3–24 months and all
remained at a constant total motor score.
Another study evaluated the effects of olanzapine in
nine HD patients [63]. The reason for olanzapine treatment
was based on the presence of psychiatric symptoms (e.g.,
depression, psychosis, disruptive behavior, and agitation)
in all participants. The mean olanzapine dose was
11.4 mg/day and mean treatment duration was 9.8 months.
A reduction of 6.5 units on the UHDRS total motor score
was observed after treatment with olanzapine, but this was
not significant.
Overall, olanzapine is safe and well tolerated. In daily
practice, olanzapine is mainly preferred due to its positive
effects on chorea, weight gain, and sleep dysfunction, and
can be recommended specifically when psychiatric symp-
toms such as irritability are also present [10, 28].
3.2.4 Risperidone
Risperidone acts as a 5-HT2A and D2 receptor antagonist
and is generally used in the treatment of schizophrenia and
the acute manic phase of bipolar disorders [64]. Although
risperidone is an atypical antipsychotic drug, it behaves
more as a typical antipsychotic drug, as there is a relatively
high risk of developing tardive dyskinesia and other
extrapyramidal effects compared to other second-genera-
tion antipsychotics [65]. Risperidone has a good oral
bioavailability of 70–85%, with peak plasma concentra-
tions reached in 1 h and a mean half-life of 22 h of the
active metabolite [58]. As risperidone is metabolized via
CYP2D6 in the liver, simultaneous use of CYP2D6 inhi-
bitors (such as fluoxetine and paroxetine) can increase the
plasma concentration of risperidone [58, 59].
The use of risperidone for the treatment of chorea in HD
is not investigated in clinical trials. Several case-reports on
risperidone describe a reduction in motor symptoms and
improvement of psychiatric symptoms [66–69].
A retrospective chart analysis study compared 17 HD
patients taking risperidone (mean dose of 2.5 mg per day)
with 12 HD patients not taking any antipsychotic medica-
tion [70]. Here, risperidone had a beneficial effect on
psychiatric symptoms associated with HD over a period of
14 months. According to the authors, risperidone also
showed a trend toward stabilizing motor decline, as the
total motor scores did not change over time.
Among HD experts, risperidone was reported by 43% of
the respondents as the first choice antipsychotic drug for
the treatment of chorea [10].
Although evidence about the safety and tolerability of
risperidone in patients with HD is lacking, the current
clinical reports suggest that risperidone might improve
motor symptoms in HD, specifically when psychiatric
symptoms are present.
3.2.5 Quetiapine
Only three case reports thus far have reported the use of
quetiapine in patients with HD [71–73]. Despite the lack of
scientific evidence, a survey among an international group
of HD experts revealed that 12% of the respondents prefer
quetiapine as a first-choice antipsychotic drug for the
treatment of chorea, especially when psychiatric symp-
toms, such as irritability, are present [10].
Quetiapine is an atypical antipsychotic drug that inter-
acts with several neurotransmitter receptors. It exhibits
high affinity for serotonin (5HT2) and dopamine D2
receptors, thus explaining the low incidence of extrapyra-
midal side effects [58]. Maximum plasma concentrations
are reached within 1–1.5 h and the drug is eliminated
through the liver with a mean half-life of approximately
6 h [58].
Two case-reports suggest that quetiapine is potentially
effective for treatment of positive psychotic symptoms in
HD [71] and for the treatment of behavioral symptoms
such as agitation, irritability, and insomnia [72]. Another
case-report of a patient with HD without psychiatric
symptoms but with severe choreiform movements revealed
an improvement on the UHDRS chorea score after 9 weeks
of treatment with 300 mg olanzapine daily [73]. In this
patient, fine motor tasks and gait markedly improved, and
the patient was able to perform better in daily tasks,
without reporting any adverse effects.
Quetiapine seems to be well tolerated; adverse effects of
quetiapine observed by HD experts are weight gain, seda-
tion, akathisia, and dry mouth [10]. Possibly due to the lack
of scientific reports, quetiapine is not often selected as a
first choice to treat chorea [10, 11].
To summarize, although there are few evidence-based
studies performed regarding the effectiveness of dopamine
antagonists as a symptomatic treatment option for reducing
chorea, dopamine antagonists seem to have a beneficial
effect on chorea in HD. Despite the lack of evidence, it is
already common to prescribe dopamine antagonists as a
first choice for treating chorea in clinical practice [10, 11].
In particular, tiapride (in European countries), olanzapine,
and risperidone are preferred among HD experts and
overall show a beneficial effect on motor symptom severity
and improvement of psychiatric symptoms in the existing
literature. When prescribing dopamine antagonists for the
treatment of chorea, it is suggested to start with a low dose,
which can be increased, depending on the presence of
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adverse effects and patients’ tolerance. Future large ran-
domized, double-blind, placebo-controlled trials of dopa-
mine antagonists are necessary to determine if these drugs
are advantageous for the treatment of chorea.
3.3 Anti-Glutamatergic Drugs
3.3.1 Amantadine
Amantadine is a noncompetitive N-methyl-D-aspartic acid
(NMDA) receptor antagonist and is commonly used in the
treatment of extrapyramidal symptoms in Parkinson’s dis-
ease (PD). Amantadine reaches peak plasma concentrations
after 1–4 h, is poorly metabolized in humans via renal
secretion (90% can be recovered unchanged in urine), and
has a relatively short half-life of 12 h in young adults [74].
Although amantadine is recommended as an alternative
for tetrabenazine by the AAN guidelines for the treatment
of chorea in HD [49], there is limited evidence about the
efficacy and safety of amantadine in patients with HD.
Two small placebo-controlled, randomized trials were
performed to assess the effects of oral amantadine on motor
and cognitive function in HD. In one study, 24 patients
with HD received amantadine (400 mg per day) or placebo
in a double-blind, crossover study for 4 weeks [75]. Results
from video assessments and live ratings of the chorea score
showed a significant reduction of 36% in the median
chorea score of the extremities at rest after treatment with
amantadine, compared to placebo. However, the effects of
amantadine on chorea and the plasma concentrations varied
considerably between patients. Also, the authors did not
report absolute differences on chorea scores as results are
only given in percentage change. In the second placebo-
controlled study, however, there was no significant change
in chorea score between placebo and amantadine [76]. In
this study, the same randomized crossover design was
performed using amantadine 300 mg per day interspersed
with placebo for 4 weeks in 25 HD patients.
A small open-label study also reported a significant
reduction of dyskinesias on the UHDRS motor score (-9.0
units) and Abnormal Involuntary Movement Scale (AIMS)
score (-7.0 units) in eight HD patients receiving 100 mg
amantadine for a 1-year period [77].
Frequent reported adverse effects during amantadine
treatment included insomnia, hallucinations and confusion,
agitation or anxiety, dry mouth, nausea, and diarrhea [75, 76].
The authors of the Cochrane review combined both ran-
domized, placebo-controlled studies to perform a meta-anal-
ysis [2]. These pooled results did not show any significant
effect of amantadine for the treatment of chorea. Furthermore,
in a survey among HD experts, the use of amantadine to treat
chorea was highly debatable and only few experts use
amantadine, especially in first- and second-line clinical
settings [10]. Based on the above-mentioned results, treatment
with amantadine showed various findings but overall does not
seem effective in reducing chorea in HD.
3.3.2 Riluzole
Riluzole is a glutamate release inhibitor that displays anti-
excitotoxic characteristics [78]. Therefore, riluzole is proposed
as a potential neuroprotective agent for treatment in HD. Peak
plasma concentrations are reached in 14 h, with a bioavail-
ability of 60%. Riluzole is eliminated via urinary excretion for
85–95% in the first 24 h after administration [78].
In HD, two small open-label studies showed significant
improvements in chorea scores in patients treated with
riluzole 100 mg/day for 6 weeks [79] and 50 mg twice
daily for 1 year [80]. The HSG therefore conducted a
multicenter, randomized, double-blind study to evaluate
the short-term, dosage-related impact of riluzole on chorea
in 63 patients with HD [81].
In this study, riluzole 100 mg/day (n = 18), riluzole
200 mg/day (n = 23), or a placebo (n = 22) was given
twice daily for 8 weeks [81]. There was a reduction in
mean chorea score of 2.2 units (SD 3.3) in the riluzole
200 mg/day group compared to the placebo group. There
were no significant differences in chorea scores between
riluzole 100 mg/day and placebo.
The total motor score of the UHDRS improved by 4.0
units (SD 7.1) for participants with riluzole 200 mg/day
and worsened by 1.6 units (SD 7.4) in the placebo group.
Adverse effects occurring during the study included
dizziness, fatigue, muscle weakness, nausea, and somno-
lence. Most importantly, riluzole caused elevation of hep-
atic liver enzymes in eight patients in the group of riluzole
100 mg/day, and 14 cases in the riluzole group of
200 mg/day. One participant had associated abdominal
pain and increased hepatic liver enzymes that resolved
upon discontinuing the drug. The authors conclude that
they were unable to confirm the effect of riluzole
100 mg/day reported in the previous open-label studies
[79–81].
Additionally, participants in all three pilot studies used
concomitant neuroleptic drugs for treatment of chorea,
complicating the interpretation of the results.
To evaluate the long-term efficacy in slowing disease
progression, a large randomized, double-blind trial of
riluzole in HD was performed [82]. In total, 537 patients
were randomized to treatment with riluzole (50 mg twice
daily) or placebo. After 3 years, 279 patients completed the
study. There was no significant change in chorea score over
time observed at any time point during the study.
Moreover, significant increased serum markers that
indicate hepatotoxicity were observed in 13 patients in the
riluzole group, of whom five patients had to discontinue,
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compared to one patient in the placebo group. The
increased incidence of elevated liver enzymes in patients
treated with riluzole is consistent in studies with riluzole
performed in patients with ALS [83].
Although the AAN guidelines suggest clinicians pre-
scribe riluzole (200 mg/day) to treat chorea, long-term
evaluation and large cohort studies showed no beneficial
effect to support this recommendation, and the AAN
recommendations were discussed critically by HD experts
[46]. Furthermore, riluzole is not prescribed by HD experts
in clinical practice [10].
3.4 Aripiprazole
Aripiprazole is a second-generation antipsychotic drug, gen-
erally prescribed in schizophrenia and schizoaffective
Table 2 Most frequently prescribed drugs for chorea in Huntington’s disease (HD)




Active depression or suicidal ideation,
psychosis, impaired hepatic function,
concomitant use of MAO-inhibitors
Reduce tetrabenazine dose with concomitant use
of fluoxetine and paroxetine
Olanzapine Sedation, weight gain, dry
mouth, Parkinsonism
None specific Drugs that induce CYP1A2 enzymes
(carbamazepine, omeprazole, rifampin) may
reduce olanzapine plasma levels. CYP1A2





None specific Drugs that induce CYP3A4 enzymes
(carbamazepine, phenobarbital, phenytoin) may
reduce risperidone plasma levels. Fluoxetine and
paroxetine can increase plasma concentration
Tiapridea Sedation, parkinsonism Prolactin-dependent tumors, history of
QT-prolongation
Concomitant use of levodopa or other dopamine
agonists is contraindicated. Sedative effect of
tiapride can be increased in combination with
antidepressants, benzodiazepines and opioids
Quetiapine Weight gain, dry mouth,
parkinsonism, sedation,
akathisia
History of QT-prolongation, neutropenia CYP3A4 inhibitors (clarithromycin, erythromycin,
ketoconazole) can increase quetiapine plasma
levels. Increase quetiapine dose with






None specific CYP2A4 or CYP2D6 inhibitors (ketoconazole,
quinidine, fluoxetine, paroxetine) can inhibit
aripiprazole elimination and cause increased
blood levels. Concomitant use of serotonergic





Myeloproliferative disorders, history of
agranulocytosis, uncontrolled epilepsy,
paralytic ileus, or hepatic dysfunction
Reduce dose when combining with fluvoxamine
and paroxetine. Drugs that induce cytochrome
P450 enzymes may decrease clozapine plasma
levels
Haloperidol Tardive dyskinesia, sedation,
parkinsonism, akathisia,
tachycardia
Coma, history of QT prolongation or
other clinical significant cardiac
diseases
CYP3A4 or CYP2D6 isoenzymes inhibitors
(venlafaxine, fluvoxamine, sertraline, buspirone,
and alprazolam)






tumors (such as pituitary tumors, breast
cancer)





Refractory epilepsy, psychosis, acute
glaucoma
Adverse effects of anticholinergic drugs may be
increased with concomitant use of amantadine.
Quinine can reduce the renal clearance of
amantadine
Drugs listed in this table are the most commonly prescribed drugs for the treatment of chorea based on international surveys among HD experts
and registered HD patients (Priller et al. [11], Orth et al. [25], Burgunder et al. [10]). Most commonly reported adverse effects, contraindications,
and drug interactions are described (Brown et al. [64], Videnovic [59])
a Tiapride is only available in European countries
Pharmacological Treatment of Chorea in HD 39
disorders. Common atypical antipsychotics are D2 receptor
antagonists, but aripiprazole acts as a partial agonist on
dopaminergic D2 and serotoninergic 5-HT1A receptors and as
an antagonist on the serotoninergic 5-HT2A receptors [84].
Therefore, aripiprazole is well tolerated and rarely causes
extrapyramidal and metabolic adverse effects in schizophre-
nia [84]. Aripiprazole is well absorbed, with peak plasma
concentrations occurring within 3–5 h of administration and
with an oral availability of 87% [58]. The mean elimination
half-life is about 75 h and occurs through hepatic metabolism
via two P450 isozymes, CYP3A4 and CYP2D6 [58].
In HD, no randomized, controlled trials have been per-
formed to investigate the effect of aripiprazole on chor-
eiform movements. Nevertheless, 11% of an international
group of HD experts prescribe aripiprazole for the treat-
ment of chorea [10].
A case report has described a beneficial effect of arip-
iprazole on choreiform movements in three advanced HD
patients [85]. Besides the presence of severe dyskinesias,
behavioral changes and mood disturbances were also
reported. Aripiprazole was well tolerated and a reduction of
choreiform movements was seen on the UHDRS total
motor score in all patients, and this remained stable over a
12-month follow-up period.
Another small crossover study compared the effects of
aripiprazole with tetrabenazine in six patients with HD
[86]. All patients received aripiprazole twice daily (mean
daily dose 10.7 mg) and tetrabenazine twice daily (mean
daily dose 95.8 mg) in random order for 3 months, with a
washout period of 3 weeks between the two drugs. Treat-
ment with aripiprazole showed a reduction of 5.2 units in
the UHDRS chorea score, whereas tetrabenazine treatment
caused a reduction of 5.4 units in the UHDRS chorea score.
HD patients treated with aripiprazole reported a better
tolerability with less sedation, depressive mood, and
sleepiness then when treated with tetrabenazine [86].
However, another study reports that the use of aripiprazole
in psychiatric disorders is associated with tardive dyski-
nesia [87]. To make a fair comparison between the efficacy
and tolerability of these two drugs, a randomized clinical
trail with a larger sample size is needed.
3.5 Other Pharmacological Preferences
Benzodiazepines (such as clonazepam and diazepam),
haloperidol, and sulpiride are also frequently prescribed
drugs to reduce chorea in daily clinical practice [10, 11, 25].
Although it is suggested that benzodiazepines have a
beneficial effect on motor signs, no clinical trials have
investigated this effect on chorea. Only two case reports
showed some favorable effect of clonazepam (dosage up to
5.5 mg per day) [88, 89], and among HD experts, clon-
azepam is only used as an adjunctive therapy [10].
Haloperidol and sulpiride are both classic first-genera-
tion antipsychotics drugs that were previously in favor for
the treatment of choreiform movements in HD [90] . Three
studies performed in the 1980s report a decrease of chorea
in HD patients treated with haloperidol using doses ranging
from 1.5 to 80 mg per day [90–92]. Sulpiride was shown to
have a positive effect on abnormal involuntary movements
in one randomized, double-blind, crossover study [93]. Due
to the high risk of adverse effects, such as tardive dyski-
nesia and drug induced-parkinsonism, and the introduction
of newer second-generation antipsychotics, these drugs are
now considered not to be beneficial to treat chorea in HD.
Still, 24% of the respondents of the international group of
HD experts preferred haloperidol as a first choice of
antipsychotic drug [10]. In Europe, an assessment of
medication use across HD patients showed that 6% of the
registered patients received haloperidol and another 6%
received sulpiride [11].
The efficacy of levetiracetam for reducing chorea has
been investigated in two small open-label studies
[94, 95]. In one study, 15 HD patients were treated with
levetiracetam as an add-on therapy and showed a sig-
nificant improvement on chorea scores after a 6-month
treatment without reporting any adverse effects [94].
Another open-label study also showed a significant
improvement on the UHDRS chorea score in nine HD
patients [95]. However, somnolence contributed to a
dropout rate of 33% and Parkinsonism was reported as
an additional adverse effect.
3.6 Potential New Treatment Options
There are currently several ongoing or recently completed
clinical trials in HD (http://www.clinicaltrials.gov [ac-
cessed 16 August 2016]). Active ongoing clinical trials
investigating potential drugs to reduce motor symptoms in
HD are summarized in Table 3.
Recently completed studies that showed no significant
benefit on motor symptoms include latrepirdine (dimebon),
ethyl-eicosapentaenoic acid, nabilone, mavoglurant
(AFQ256), and Sativex (a cannabinoid drug) [96–100].
Promising treatment options are deutetrabenazine and prido-
pidine, which are being developed to target motor symptoms in
HD.
3.6.1 Deutetrabenazine
SD-809 or deutetrabenazine is a newly developed VMAT2
inhibitor that is structurally related to tetrabenazine in a
deuterated form. Deuterium is a naturally occurring, non-
toxic form of hydrogen and can create stronger bonds with
carbon than with hydrogen [101]. The specific sites of
deuterium placement in deutetrabenazine are thought to
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increase the half-life of active circulating metabolites
compared to tetrabenazine without changing its target
pharmacology.
Due to the lower peak plasma concentrations, it is
suggested that deutetrabenazine can reduce the peak dose
side effects that occur when treating with tetrabenazine
[102]. However, it is not known what adverse effects might
occur if a higher dosage of deutetrabenazine is needed for
effective treatment.
Recently, the FIRST-HD study, a randomized, con-
trolled trial was conducted by the HSG to evaluate the
efficacy, safety, and tolerability of deutetrabenazine for the
treatment of chorea in HD [103]. In total, 90 participants
were enrolled to receive either deutetrabenazine (n = 45)
or placebo (n = 45) for 12 weeks, including an 8-week
titration phase and a 4-week maintenance phase followed
by a 1-week washout. Patients gradually increased the dose
weekly by 6 mg per day, with a maximum dose of 48 mg
per day, or when a clinically significant serious adverse
event occurred.
Deutetrabenazine significantly reduced chorea in
patients with HD based on a reduction of 2.5 points on the
total maximal chorea score of the UHDRS compared to
placebo (p\ 0.001). Deutetrabenazine also significantly
improved overall motor function based on a reduction of
4.0 points on the total motor score of the UHDRS com-
pared to placebo (p = 0.002). The safety profile of
deutetrabenazine was similar to placebo. The most com-
monly reported adverse event in the deutetrabenazine
group was somnolence, which generally resolved without
reducing the dosage. Also, a weight increase of 0.7 on the
body mass index (BMI) scale was reported for the
deutetrabenazine group compared to placebo (p = 0.002).
Subjectively, patients treated with deutetrabenazine repor-
ted more overall functional improvement then patients in
the placebo group.
Long-term use of deutetrabenazine is currently being
examined in an ongoing open-label safety study (the ARC-
HD study). This study aims to evaluate the safety, tolera-
bility, and pharmacokinetics of deutetrabenazine in
patients with HD switching from tetrabenazine to
deutetrabenazine. Preliminary results of this study after
8 weeks of treatment with deutetrabenazine showed a
significant improvement on the total chorea motor score in
37 patients with HD that switched overnight from three
times daily tetrabenazine to twice daily deutetrabenazine
[104].
Thus far, deutetrabenazine seems to be effective in
treating chorea in HD with no significant adverse effects
compared with placebo. Currently, the FDA has accepted
the New Drug Application (NDA) for deutetrabenazine for
the treatment of chorea and the Prescription Drug User
Free Act (PDUFA) date is set for 3 April 2017.
3.6.2 Pridopidine
Pridopidine (formerly known as ACR-16) is a recently
developed drug that belongs to a new class of pharmaco-
logical agents known as dopidines, which act as dopamine
stabilizers. By binding to striatal dopamine D2 receptors,
pridopidine can reverse and improve behavioral states by
modulating hyperactivity or hypoactivity of the dopamin-
ergic system, without having major effects on normal
psychomotor function [105, 106].
Pridopidine is orally administered and has a rapid
absorption, with peak plasma concentrations within
0.5–4 h and an elimination half-life between 10 and 14 h,
with elimination partly by urinary excretion and partly by
hepatic metabolism [106].
Three randomized, placebo-controlled clinical studies
have investigated the efficacy and safety of pridopidine in
HD [107–109]. The primary outcome measure for all
studies was change in the modified motor score (mMS),
comprising 13 items from the UHDRS (the items chorea,
dystonia, and ocular movements were excluded to reduce
potential noise in the motor results), with a maximum score
of 52.
The first study examined the efficacy of 50 mg prido-
pidine (n = 28) compared to placebo (n = 30) for 4 weeks
[107]. In this study, patients treated with pridopidine
showed improved modified motor scores after 4 weeks but
this improvement of 2.9 units in the pridopidine group was
not significantly different from the 0.9-unit improvement in
the placebo group.
The HART (Huntington’s Disease ACR16 Randomized
Trial) study was conducted in 227 patients with HD as a
dose-finding study (20 mg, 45 mg, and 90 mg pridopidine
daily) for 12 weeks [108]. Simultaneously with the HART
study, the MermaiHD (Multinational European Multicenter
ACR16 study in Huntington’s Disease) study compared
45 mg (n = 148) and 90 mg (n = 145) pridopidine daily
with placebo (n = 144) after 26 weeks treatment [109].
In both the HART and MermaiHD studies, there was a
trend for a positive effect on the mMS for the 45 and 90 mg
pridopidine dosages, but this did not reach the pre-specified
significance criteria [108, 109]. Still, significant improve-
ments in the pridopidine group were found for the UHDRS
total motor score in both studies. This was primarily driven
by improvements on dystonia and eye movement scores.
Overall, pridopidine was well tolerated with an adverse
event profile similar to placebo. Reported adverse effects
include falls, fatigue, depression, agitation, nausea, diar-
rhea, and dizziness [107–109].
Although these three studies did not detect any signifi-
cant results on their primary outcome measure (mMS), a
marginal effect was seen in the total motor score for the
highest dose range. Higher dosages of pridopidine (90, 135,
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180, and 225 mg daily) have been recently studied in the
PRIDE-HD study, a large, multicenter, double-blind, dose-
finding phase II trial, which will also assess the long-term
safety in an open-label extension study [110, 111]. Pre-
liminary results of this study were presented at the 9th
European Huntington Disease Network Plenary Meeting in
September 2016 and showed that an unexpectedly high
placebo effect limited the ability to determine treatment
effects of pridopidine on motor symptoms measured using
the UHDRS-TMS. Thus, pridopidine failed to meet the
primary endpoint in this trial, also in the group of patients
taking lower dosages. In the early stage HD subpopulation,
a slight improvement in the UHDRS-TMS was observed at
specific dosages. Also, a potential improvement on disease
progression was seen as measured with the Total Func-
tional Capacity (TFC) score compared to placebo. Since
the effect on the TFC score was an explorative endpoint,
further evaluation of the results will need to determine its
potential effect on disease progression and reducing chorea
in patients with HD.
4 Conclusions
This review provides an overview of the current evidence
and clinical experience on pharmacological options for the
treatment of chorea in HD. HD is a disease with a
heterogeneous combination of motor disturbances, psy-
chiatric symptoms, and cognitive impairment. Thus, treat-
ment options need to be carefully evaluated on an
individual basis prior to initiating pharmacological
treatment.
A longitudinal study showed that choreatic symptoms
decrease over time and hypokinetic-rigid symptoms
Table 3 Ongoing clinical trials for treatment of chorea in Huntington’s disease
Study Phase Design Study agent Outcome measures Trial length
ARC-HD
(NCT01897896)
III Multicenter, open-label, long-





Incidence of adverse events, change from
baseline in clinical laboratory parameters,
vital signs and UHDRS
Up to
58 weeks
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Change in index of brain energy restoration
using 31-P MRS and change of caudate




Information on current ongoing clinical trials investigating the efficacy on chorea in patients with Huntington’s disease obtained from http://
www.clinicaltrials.gov [accessed 16 August 2016]
HD Huntington’s disease, UHDRS–TMS Unified Huntington’s Disease Rating Scale–Total Motor Score, mPPT modified Physical Performance
Test, 31-P MRS 31-Phosophorus Magnetic Resonance Spectroscopy, MRI magnetic resonance imaging, HD-CAB Huntington’s Disease Cog-
nitive Assessment Battery
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become more pronounced [112]. Therefore, annual follow-
up visits in the outpatient clinic or by using the longitudinal
observational REGISTRY and ENROLL-HD studies can
be useful to assess if disease progression warrants a
reduction in treatment dosage or a switch in prescribed
drugs.
Despite the lack of evidence-based randomized, con-
trolled studies, dopamine antagonists seem to have a ben-
eficial effect on chorea in HD. Many clinicians use
olanzapine, risperidone, or tiapride as a first choice of
treatment, as they additionally have a positive effect on
sleep dysfunction (due to the sedative effects), mood dis-
turbances, and weight gain [113].
Tetrabenazine is the only drug for the treatment of
chorea in HD that is approved by the FDA and the risk of
developing a metabolic syndrome or tardive dyskinesia is
lower than seen in antipsychotic drugs. In large randomized
clinical trials, tetrabenazine proved to be beneficial in
reducing chorea [39]. However, because of the increased
risk of depression and suicidal behavior, the use of tetra-
benazine can be limited. Hence, the recently developed
deutetrabenazine forms an interesting pharmacological
agent, as preliminary results show a beneficial effect on
chorea with less adverse effects than seen when treating
with tetrabenazine [103].
Overall, assessing the efficacy of drugs in HD patients is
challenging, as most studies are underpowered, have a
small treatment duration, use different (sometimes not
validated) rating scales as outcome measures, and do not
have a randomized, double-blind study design. Also, there
is limited interest from pharmaceutical companies to con-
duct a trial for commonly used antipsychotic drugs that
have no patent rights. Therefore it is meaningful to not only
focus on evidence-based results but also on treatment
guidelines developed by expert opinions [46].
The UHDRS is frequently used as a primary endpoint in
clinical therapeutic trials, as this clinical rating scale is
practical in assessing general motor impairment. Still, it
might not be the most sensitive tool to detect small changes
in the severity of choreiform movements, as the scale
seems to be less sensitive in detecting mild clinical signs
[3].
New innovative tools are currently used to measure
chorea objectively, such as quantitative assessment of
chorea with choreomotography, a noninvasive and easy
applicable method that might be a valuable primary end-
point for future clinical trials [114].
More randomized, controlled trials and long-term eval-
uation on symptomatic treatment for chorea are currently
ongoing and are needed to better assess the efficacy of
potentially effective drugs. Also, future studies comparing
different treatment options are interesting for analyzing
between-drug efficacy and adverse effects.
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